Search
Celiprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnCeliprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesBiricodar
go.drugbank.com/drugs/DB04851InvestigationalThe pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).
Categories: P-glycoprotein inhibitorsTirapazamine
go.drugbank.com/drugs/DB04858InvestigationalTirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hy...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesNilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered si...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2C8 InducersVildagliptin
go.drugbank.com/drugs/DB04876ApprovedInvestigationalVildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are i...
Categories: P-glycoprotein substratesLanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalLanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analo...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsPhenylbutyric acid
go.drugbank.com/drugs/DB06819ApprovedInvestigationalPhenylbutyric acid is a fatty acid and a derivative of butyric acid naturally produced by colonic bacteria fermentation. It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsTranilast
go.drugbank.com/drugs/DB07615InvestigationalTranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates(R)-warfarin
go.drugbank.com/drugs/DB08496ExperimentalWarfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways. S-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.
Categories: Cytochrome P-450 CYP1A1 Substrates, Cytochrome P-450 CYP1A2 SubstratesBupranolol
go.drugbank.com/drugs/DB08808ExperimentalBupranolol is a non-selective beta blocker with potency similar to propanolol. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates